Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More
Xconomy
OCTOBER 7, 2016
. —Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. The funding could be as much as $100 million, and the first grants will be announced in 2017. —The U.S. —The U.S.
77 
Let's personalize your content